The Pharma Paradox: Predictable Markets, Unpredictable Winners

Separating patient’s demand certainty from pharma’s execution risk

Prepared by Richstorm.co

Key Takeaways

• Disease prevalence and demographic trends are public, slow-moving data that make market size genuinely predictable years in advance.

• Whether a specific drug clears three separate gates — biological, regulatory, and commercial — remains close to a coin flip regardless of platform maturity.

• Large acquirers narrow their search to a handful of therapeutic areas before sizing any market, driven by franchise fit and revenue timing, not unmet need alone.

• Small biotechs can target the same large markets as mega-caps; company size determines when a player enters and how it captures value, not whether it can compete for demand.

• Predictable demand tells an investor how big the prize is; it says nothing about which company wins it.

Pharma has a reputation for being more predictable than other sectors, because two of its three core ingredients are visible in advance: the disease exists, and the market exists. The third ingredient — whether a specific company's drug actually clears every gate between the lab and the patient — is not. This piece separates the two, and shows how the same split shapes decisions from an investor's stock pick to a mega-cap's acquisition strategy.

The Predictable Half: Sizing the Need

Three things make pharma demand unusually easy to size years ahead of time, using data that is already public.

Epidemiology data — disease prevalence, incidence, and how those numbers are trending — is tracked by public health agencies and updated on a known schedule (CDC, WHO, disease registries). A 6-million-patient disease growing 3% a year is a number an investor can simply look up, well before any specific company benefits from it.

Standard-of-care gap analysis measures how weak the current treatment is: low response rates, harsh side effects, or an inconvenient dosing schedule all represent unclaimed value. The wider the gap, the more room a working new drug has to capture.

Demographic trend extrapolation is one of the most reliable forecasts available for age-related disease, because the people who will be 70 years old in 2035 are already alive today — they only need to be counted forward.

Together, these three tools answer one question with real confidence: is this a big, durable market or a small, shrinking one. They say nothing about who wins it.

How Big Pharma Narrows the Field Before It Even Sizes the Market

A mega-cap doesn't survey every disease area and rank them by need. Internal constraints narrow the field to a handful of candidates first, and only then does the demand-sizing work above get applied.

Table: What narrows a mega-cap's search before market sizing begins

This funnel is the practical, upstream version of step one in The Acquirer's Playbook: How a Pharma VP Actually Chooses What to Buy — establishing a strategic thesis before any target is identified. The demand-sizing tools above are how that thesis gets tested, once the field is already narrow.

The Coin Flip: Three Gates of Execution Risk

A real, sized market doesn't guarantee a company captures it. Every drug has to clear three separate gates, and clearing one says nothing about the others.

Table: The three gates a drug has to clear

Moderna and Johnson & Johnson's COVID vaccine programs are the clearest case study of how little platform maturity determines the outcome — covered in full in our earlier piece, One Pandemic, Two Bets, Opposite Outcomes. Moderna entered with no patent and no clinical data, built on a single peer-reviewed finding. J&J entered with a mature, previously-used adenovirus vector platform. The less-proven platform produced a validated, multi-billion-dollar product; the more mature platform was pulled after a safety signal and over $1.5 billion in disclosed exit costs. A mature platform did not reduce execution risk, and an unproven one did not prevent the win.

Small Players Go First, Mega-Caps Buy the Risk Down

Small biotechs are not blocked from targeting the same large markets a mega-cap wants. A $500 million peak-sales drug can be a major win for a company that raised $80 million in venture funding, even though that same market would be too small to matter to a $400 billion company. Size determines when a player can afford to enter and how it eventually captures value — not whether it can compete for demand.

Not every small player arrives at that market the same way — the table below breaks out who sizes need up front versus who backs into it. But whichever path a company takes, if it clears gate one and the science starts working, it has de-risked a mega-cap's eventual purchase. Mega-caps then buy in once execution risk has already dropped — roughly 65% of pharma acquisitions target pre-revenue companies, precisely because the acquirer is paying for a market opportunity and a reduced version of the coin flip, packaged together.

Unmet-need sizing isn't gatekept by company size. What size determines is who enters early at higher risk, and who waits to buy the risk down.

Who Actually Estimates Market Size

Formal demand-sizing shows up at more points in the chain than it first appears — and understanding who does it, and why, matters more than trying to replicate their work from scratch.

Table: Who sizes pharma demand, and for what purpose

This sizes the prize. It never picks the winner — that judgment still runs through the three gates above, and no market-sizing exercise substitutes for it.

The Closing Scorecard

Predictable: how large the need is, and how long it will last. Not predictable: which molecule clears biological, regulatory, and commercial risk to actually capture it. The investable edge in pharma isn't knowing the market is real — everyone with public data access can see that. It's knowing exactly which question is still a coin flip before treating the rest of the thesis as settled.